Verve Therapeutics (NASDAQ:VERV) Upgraded by Cantor Fitzgerald to “Overweight” Rating

Cantor Fitzgerald upgraded shares of Verve Therapeutics (NASDAQ:VERV) from a neutral rating to an overweight rating in a report released on Tuesday, MarketBeat.com reports.

Several other research analysts have also recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday. Royal Bank of Canada lowered their target price on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright boosted their price target on Verve Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a report on Monday. William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, Guggenheim restated a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.75.

Verve Therapeutics Stock Performance

VERV opened at $4.97 on Tuesday. The firm has a market cap of $441.32 million, a PE ratio of -2.02 and a beta of 1.86. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The firm’s fifty day moving average is $5.84 and its two-hundred day moving average is $5.92.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Equities analysts forecast that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Trading of Verve Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BVF Inc. IL increased its position in shares of Verve Therapeutics by 962.2% during the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock worth $38,939,000 after purchasing an additional 6,254,050 shares during the last quarter. State Street Corp grew its stake in shares of Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after buying an additional 903,809 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in Verve Therapeutics by 57.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock worth $21,372,000 after buying an additional 1,382,176 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Verve Therapeutics by 18.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company’s stock valued at $10,423,000 after buying an additional 288,678 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Verve Therapeutics by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company’s stock valued at $9,172,000 after buying an additional 25,093 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.